The Role of ADT in Localized or Locally Advanced Prostate Cancer

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

EP: 1.Prostate Cancer Treatment: The Evolving Therapeutic Landscape

EP: 2.The Heterogeneity of Prostate Cancer

Now Viewing

EP: 3.The Role of ADT in Localized or Locally Advanced Prostate Cancer

EP: 4.EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

EP: 5.Treatment Considerations in Nonmetastatic CSPC

EP: 6.Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

EP: 7.Treatment Options in Castration-Resistant Prostate Cancer

EP: 8.The Relationship Between Prostate Cancer and Cardiovascular Disease

EP: 9.Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

EP: 10.ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Related Videos

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.